🚨 #ESMO26 Breast Cancer: Top Ten by @OncoAlert 🎗️ The abstracts our faculty flagged as must-know from MADRID🇪🇸 👇 1️⃣ PANKU-Breast01 (LBA50): iza-bren in HR+/HER2− mBC 2️⃣ FOURLIGHT-1 (1842O): atirmociclib + fulvestrant post-CDK4/6i 3️⃣ NATALEE (LBA25): 6-year OS for adjuvant ribociclib 4️⃣ APEX-Breast01 (LBA27): TQB2102 in HER2-low 5️⃣ KEYNOTE-B49 (LBA51): pembro + chemo in HR+/HER2− 6️⃣ HORIZON-Breast06 (LBA13): SHR-A1811 in HER2-low 7️⃣ POP-DURVA (LBA26): preop durvalumab in stage I TNBC 8️⃣ SWITCH (4RO): ADC target switching after prior ADC 9️⃣ postMONARCH (1RO): OS for abemaciclib + fulvestrant 🔟 DESTINY-Breast09 (LBA49): T-DXD + P with baseline brain mets #BreastCancer @matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @hoperugo @stolaney1 @BianchiniGP @aftimosp @kevinpunie @ElisaAgostinett @to_be_elizabeth @GaiaGriguolo @JankovicK @double_whammied @maryam_lustberg @raalbany @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @LoiSher @SirohiBhawna @jamecancerdoc @nataliagandur @acampsmalea @FernandoOnco @realbowtiedoc @Lucarecco @AmandaNizamMD @scocmem @MarioBalsaMD @Dr_Oncologista